business

Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance

Yahoo Finance · May 18, 2026, 12:32 PM · Also reported by 1 other source

Read full story on Yahoo Finance → More top stories

Also covered by

Bloomberg Markets Blue Owl Fund Returns to Market With $400 Million Bond Offering

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance

Also covered by

More in business